Literature DB >> 25464433

Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients.

Ludovica Perri1, Daniele Pastori1, Pasquale Pignatelli1, Francesco Violi1, Lorenzo Loffredo2.   

Abstract

BACKGROUND: Atrial fibrillation is associated with multiple atherosclerotic risk factors and predisposes to cardiovascular events (CVE). Endothelial dysfunction is associated with atherosclerosis and independently predicts CVE. The aim of the study was to evaluate the association between endothelial dysfunction, as assessed by flow-mediated dilation (FMD), and CVE in AF patients.
METHODS: We prospectively measured FMD in 514 non-valvular AF patients on anticoagulant treatment with vitamin K antagonists. Patients were followed-up for a mean time of 23.5 months. The main composite outcome of the study was the occurrence of stroke/TIA, myocardial infarction, urgent revascularization and cardiovascular death.
RESULTS: Median value of FMD was 4.6% [IQR 1.46-8.00]. A CVE occurred in 44 patients (8.56%):non-fatal myocardial infarction (MI) in 7, fatal MI in 2, stent/coronary artery by-pass graft (CABG) in 10, ischemic non-fatal stroke in 10, fatal stroke in 3, transient ischemic attack (TIA) in 1, and cardiovascular death in 11 patients. Patients who experienced a CVE showed significantly reduced FMD compared to those who did not (3.06% [IQR 0.00-6.00] vs 4.67% [IQR 1.58-8.22], p=0.027). During a mean follow-up of 23.5 months, the rate of CVE was significantly higher in subjects with FMD below median (<4.6%) than in those with FMD above median (27 vs 17, log-rank test p=0.006). COX analysis demonstrated that low FMD (below median) (HR: 2.20, CI 95%:1.13-4.28, p=0.020), age (HR: 1.08, CI 95%: 1.03-1.12, p<0.001), smoking (HR: 4.15, CI 95%: 1.63-10.6, p=0.003) and history of stroke/TIA (HR: 2.38, CI 95%: 1.13-5.04, p=0.023) independently predicted CVE.
CONCLUSIONS: In AF patients low FMD is associated with increased risk of CVE suggesting that impaired artery dilatation predisposes to atherosclerotic complications.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Endothelial dysfunction; Flow mediated diolation; Myocardial infarction

Mesh:

Year:  2014        PMID: 25464433     DOI: 10.1016/j.ijcard.2014.10.039

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  Aging-Related Decline of Autophagy in Patients with Atrial Fibrillation-A Post Hoc Analysis of the ATHERO-AF Study.

Authors:  Francesco Versaci; Valentina Valenti; Maurizio Forte; Vittoria Cammisotto; Cristina Nocella; Simona Bartimoccia; Leonardo Schirone; Sonia Schiavon; Daniele Vecchio; Luca D'Ambrosio; Giulia Spinosa; Alessandra D'Amico; Isotta Chimenti; Francesco Violi; Giacomo Frati; Pasquale Pignatelli; Sebastiano Sciarretta; Daniele Pastori; Roberto Carnevale
Journal:  Antioxidants (Basel)       Date:  2022-04-01

Review 2.  Nonalcoholic fatty liver disease as a multi-systemic disease.

Authors:  Hakan Fotbolcu; Elçin Zorlu
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

Review 3.  Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis.

Authors:  Licia Polimeni; Maria Del Ben; Francesco Baratta; Ludovica Perri; Fabiana Albanese; Daniele Pastori; Francesco Violi; Francesco Angelico
Journal:  World J Hepatol       Date:  2015-06-08

Review 4.  Endothelial function in patients with atrial fibrillation.

Authors:  Ahsan A Khan; Graham N Thomas; Gregory Y H Lip; Alena Shantsila
Journal:  Ann Med       Date:  2020-01-10       Impact factor: 4.709

5.  Predictive value of CHADS2 and CHA2DS2-VASc scores for acute myocardial infarction in patients with atrial fibrillation.

Authors:  Hui Pang; Bing Han; Qiang Fu; Zhenkun Zong
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

6.  Applying the CHA2DS2-VASc score to predict the risk of future acute coronary syndrome in patients receiving catheter ablation for atrial fibrillation.

Authors:  Ching-Yao Chou; Yun-Yu Chen; Yenn-Jiang Lin; Kuo-Liong Chien; Shih-Lin Chang; Ta-Chuan Tuan; Li-Wei Lo; Tze-Fan Chao; Yu-Feng Hu; Fa-Po Chung; Jo-Nan Liao; Chin-Yu Lin; Ting-Yung Chang; Shih-Ann Chen
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-28

Review 7.  A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.

Authors:  Luxiang Shang; Ling Zhang; Yankai Guo; Huaxin Sun; Xiaoxue Zhang; Yakun Bo; Xianhui Zhou; Baopeng Tang
Journal:  Front Cardiovasc Med       Date:  2021-07-01

Review 8.  Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.

Authors:  Francesco Violi; Elsayed Z Soliman; Pasquale Pignatelli; Daniele Pastori
Journal:  J Am Heart Assoc       Date:  2016-05-20       Impact factor: 5.501

Review 9.  The Effects of Ischemic Preconditioning Supplementation on Endothelial Function: A Systematic Review and Meta-Analysis.

Authors:  Xufang Gu; Zhichao Liu; Shengwei Gao; Li Ma; Jinhong Chen; Zhenxing Wang; Anmin Lu; Zhizhong Wang; Baohe Wang; Yuhong Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-26       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.